EURURO Vol. 72 No. 3

E71 476

[2] Halabi S, Lin C-Y, Kelly WK, et al. Updated prognostic model for
predicting overall survival in first-line chemotherapy for
patients with metastatic castration-resistant prostate cancer.
J Clin Oncol 2014;32:671–7
.
[3] Seyednasrollah F, Mahmoudian M, Rautakorpi L, et al. How reliable
are trial-based prognostic models in real-world patients with met-
astatic castration-resistant prostate cancer? Eur Urol 2017;71:838–
40 .
Fatemeh Seyednasrollaha,b
Mehrad Mahmoudiana,c
Liisa Rautakorpid
Outi Hirvonend,e
Tarja Laitinenf,g
Sirkku Jyrkkio¨d
Laura L. Eloa,*
aTurku Centre for Biotechnology, Turku, Finland
bDepartment of Mathematics and Statistics, University of Turku, Turku,
Finland
c Department of Information Technology, University of Turku, Turku, Finland
dDepartment of Oncology and Radiotherapy, Turku University Central
Hospital, Turku, Finland
eDepartment of Clinical Oncology, University of Turku, Turku, Finland
f Department of Pulmonary Diseases and Clinical Allergology, Turku
University Hospital and University of Turku, Turku, Finland
gCentre for Clinical Informatics, Turku University Hospital, Turku, Finland
*Corresponding author. Computational Biomedicine and Bioinformatics,
Turku Centre for Biotechnology, Tykisto¨katu 6, FI-20520 Turku, Finland.
Tel. +358 2 [4_TD$DIFF]3338009; Fax: +358 2 [5_TD$DIFF]2158808.
E-mail address: (L.L. Elo).
April 24, 2017
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 7 0 – e 7 1 e71